William Harmon, MD
Urology · San Antonio, TXNPI 1104806207
Payments from drug & device makers
Across 119 payments — averaging $82.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SN Holdings, LLC$3K
- Johnson & Johnson$2K
- Intuitive Surgical$1K
- Myriad Genetic Laboratories, Inc.$900
- Merck$454
- Blue Earth Diagnostics$372
- plus $2K from 27 others
What the payments were for
- Consulting fees$2,28823%
- Speaking & faculty fees$1,00010%
- Travel & lodging$2,05421%
- Food & beverage$4,29444%
- Education$1982%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SN Holdings, LLC | 9 | $2,617 |
| Johnson & Johnson | 14 | $2,216 |
| Intuitive Surgical | 17 | $1,318 |
| Myriad Genetic Laboratories, Inc. | 2 | $900 |
| Merck | 12 | $454 |
| Blue Earth Diagnostics | 5 | $372 |
| Novartis | 11 | $330 |
| Lazarus 3d | 1 | $239 |
| Boston Scientific | 4 | $197 |
| Astellas Pharma US Inc | 4 | $148 |
| Calyxo, Inc. | 1 | $142 |
| Sumitomo Pharma America, Inc. | 6 | $127 |
| Coloplast | 1 | $110 |
| Medtronic | 3 | $106 |
| Pfizer | 4 | $63 |
| Axonics, Inc. | 2 | $53 |
| Myovant Sciences Inc. | 2 | $51 |
| Dendreon Pharmaceuticals LLC | 2 | $46 |
| Antares Pharma, Inc. | 3 | $43 |
| Dornier Medtech America, Inc | 1 | $42 |
| Foundation Medicine, Inc. | 2 | $39 |
| AstraZeneca | 1 | $30 |
| Procept Biorobotics Corporation | 1 | $29 |
| Corcept Therapeutics | 1 | $28 |
| Photocure Inc | 1 | $25 |
| Verity Pharmaceuticals Inc. | 1 | $23 |
| Olympus America Inc. | 1 | $17 |
| Halozyme Inc | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
| Tolmar Pharmaceuticals, Inc. | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $13 |
| EDAP Technomed Inc | 1 | $7 |
| Urogpo LLC | 2 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$1,879
- Da Vinci Surgical System$1,225
- Prolaris$450
- myRisk$450
- POSLUMA$305
- Pre-Sure$239
- CVAC Aspiration System$142
- AMS$141
- SUPRIS$110
How this compares
$9,834 in reported general payments places this provider in the 70th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 116 | $107,830 |
| Everolimus | 17 | $51,176 |
| GemtesaVibegron | 35 | $30,339 |
| Dutasteride | 258 | $8,991 |
| Tamsulosin Hcl | 541 | $8,535 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 36 | $6,645 |
| Trospium Chloride ErTrospium Chloride | 22 | $5,677 |
| Potassium Citrate ErPotassium Citrate | 49 | $5,310 |
| Finasteride | 341 | $3,944 |
| Silodosin | 31 | $2,966 |
| Testosterone Cypionate | 19 | $2,171 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 84 | $2,045 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 40 | $1,987 |
| NitrofurantoinNitrofurantoin Macrocrystal | 18 | $993 |
| Estradiol | 13 | $802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $148 | $107,830116 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $127 | $30,33935 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 878 urology providers in Texas.
Other urology in San Antonio
- Jose de la CerdaSan Antonio$9M
- Daniel SaltzsteinSan Antonio$5.8M
- Daniel ZainfeldSan Antonio$4.7M
- Kenneth StallmanSan Antonio$1.3M
- Naveen KellaSan Antonio$1M
- Robert SvatekSan Antonio$818K
- Leroy JonesSan Antonio$556K
- Christopher CantrillSan Antonio$348K
- Maurilio Garcia-GilSan Antonio$296K
- Zvi SchiffmanHouston$17.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.